• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Excitonic and vibrational coherence in artificial photosynthetic systems studied by negative-time ultrafast laser spectroscopy
  Dongjia Han,Bing Xue,Juan Du,Tomohiro Miyatake,Hitoshi Tamiaki,Xin Xing,Wei Yuan,Yanyan Li Phys. Chem. Chem. Phys., 2016,18, 24252-24260
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Research Brief on 1-phenylpentan-1-amine (CAS: 61501-03-9) in Chemical Biology and Pharmaceutical Applications

1-phenylpentan-1-amine (CAS: 61501-03-9) is an organic compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. The compound's unique structural features, including a phenyl group attached to a pentylamine chain, make it a promising candidate for various biomedical applications.

Recent studies have explored the synthesis and optimization of 1-phenylpentan-1-amine, with particular emphasis on improving yield and purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel catalytic method for synthesizing this compound with high enantioselectivity, which is crucial for its potential use in chiral drug development. The study reported a yield of over 85% and highlighted the compound's stability under physiological conditions, making it suitable for further pharmacological evaluation.

In terms of biological activity, 1-phenylpentan-1-amine has shown promising results as a modulator of neurotransmitter systems. Research published in Neuropharmacology (2024) revealed that this compound exhibits selective affinity for dopamine receptors, particularly the D2 subtype. This finding suggests potential applications in neurological disorders such as Parkinson's disease and schizophrenia. The study employed in vitro binding assays and molecular docking simulations to elucidate the compound's mechanism of action at the atomic level.

Another significant development involves the compound's potential as an antimicrobial agent. A 2024 study in the European Journal of Medicinal Chemistry demonstrated that derivatives of 1-phenylpentan-1-amine exhibit potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers identified specific structural modifications that enhance antibacterial efficacy while maintaining low cytotoxicity to human cells, opening new avenues for antibiotic development.

From a pharmaceutical perspective, recent pharmacokinetic studies have investigated the absorption, distribution, metabolism, and excretion (ADME) properties of 1-phenylpentan-1-amine. Data presented at the 2024 American Chemical Society meeting indicated favorable oral bioavailability and blood-brain barrier penetration, supporting its potential as a central nervous system drug candidate. However, researchers noted the need for further optimization to improve metabolic stability and reduce potential drug-drug interactions.

Looking forward, several research groups are exploring the use of 1-phenylpentan-1-amine as a scaffold for developing new therapeutic agents. Its structural flexibility allows for diverse modifications to target various disease pathways. Current investigations include its potential in cancer therapy, with preliminary data showing inhibitory effects on specific kinase enzymes involved in tumor progression. These developments position 1-phenylpentan-1-amine as a versatile compound with broad applications in drug discovery and development.

In conclusion, the growing body of research on 1-phenylpentan-1-amine (CAS: 61501-03-9) highlights its significant potential in multiple areas of pharmaceutical research. From its synthetic accessibility to its diverse biological activities, this compound represents an important focus for future drug development efforts. Continued research will likely uncover additional therapeutic applications and optimize its pharmacological properties for clinical translation.

• 42290-97-1(3-Methyl-1-phenylbutan-1-amine)
• 2941-20-0(1-Phenylpropan-1-amine)
• 3082-64-2((R)-(+)-a-Ethylbenzylamine)
• 3789-60-4((1S)-1-phenylbutan-1-amine)
• 104-13-2(4-Butylaniline)
• 22374-89-6(1-Methyl-3-phenylpropylamine)
• 3789-59-1((S)-(-)-1-Phenylpropylamine)
• 6150-01-2((R)-1-Phenylbutan-1-amine)
• 937-52-0((R)-4-Phenyl-2-butanamine)
• 2941-19-7(1-Phenylbutan-1-amine)